In October 2019, the FDA approved the use of sacubitril/valsartan for use in children older than 1 year of age with symptomatic HFrEF based on a PANORAMA-HF trial which showed reductions in the cardiac biomarker NT-proBNP in pediatric patients. This evidence concerns the gene NPPB and hydrops fetalis.